Topics:

Phase I/II Trial of AGS-003

Phase I/II Trial of AGS-003

DURHAM, North Carolina—Argos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.